Related Experiment Video
Updated: Jun 13, 2026
06:20
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Biomarkers in radiation oncology
Andrea L Russo1, Deborah Citrin, Kevin Camphausen
1National Cancer Institute, Radiation Oncology Branch, 10 Center Drive 3B42, Bethesda, MD, USA.
Biomarkers in Medicine
|May 19, 2010
Summary
Biomarker discovery for cancer radiation therapy is advancing rapidly. Researchers are exploring soluble biomarkers in serum and urine as alternatives to tissue-based immunohistochemistry (IHC) for improved clinical use.
Area of Science:
- Oncology
- Biomarker Research
- Radiation Therapy
Background:
- Biomarker discovery for cancer patients undergoing radiation therapy is accelerating.
- Immunohistochemistry (IHC) on tumor tissue is the predominant method for identifying predictive biomarkers.
- Challenges with IHC include tissue accessibility, reproducibility, and standardization.
Purpose of the Study:
- To explore alternative methods for biomarker discovery in radiation oncology.
- To investigate the potential of soluble biomarkers in non-tumor biospecimens (serum, urine) as alternatives to tissue-based markers.
- To emphasize the need for standardization in biomarker analysis for clinical translation.
Main Methods:
- Review of existing biomarker studies in radiation oncology.
- Comparison of immunohistochemistry (IHC) on tissue specimens with analysis of soluble biomarkers in serum and urine.
- Identification of specific biomarkers (e.g., VEGF, EGFR, YKL-40, Rad51, matrix metallopeptidase-2).
Main Results:
- Several pre-radiation biomarkers (e.g., VEGF, EGFR, YKL-40, Rad51) identified via IHC correlate with poor outcomes.
- Soluble biomarkers (e.g., YKL-40, VEGF, matrix metallopeptidase-2) in serum and urine also show predictive value.
- Non-tumor biospecimens offer a promising alternative to tumor tissue for biomarker studies.
Conclusions:
- Soluble biomarkers represent a viable alternative to tissue-based markers in radiation oncology.
- Standardization of sample collection, processing, storage, and analysis is crucial for the clinical adoption of soluble biomarkers.
- Further research and standardization efforts are needed to translate these findings into routine clinical practice.
